IPP Bureau

Somaiya Vidyavihar University hosts conference on ‘Clinical Translation of Biomaterials for Future Healthcare’
Somaiya Vidyavihar University hosts conference on ‘Clinical Translation of Biomaterials for Future Healthcare’

By IPP Bureau - February 25, 2025

Briefs: Syngene International and Cipla
Briefs: Syngene International and Cipla

By IPP Bureau - February 23, 2025

Cipla Limited has received final approval from the USFDA for the New Drug Application submitted for ‘Nilotinib Capsules 50, 150 and 200 mg’

Sandeep Rao appointed MD and CEO of Solar Active Pharma Sciences
Sandeep Rao appointed MD and CEO of Solar Active Pharma Sciences

By IPP Bureau - February 23, 2025

Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025

5.1 lakh TB patients notified across India
5.1 lakh TB patients notified across India

By IPP Bureau - February 23, 2025

Among those identified, 2.4 lakh patients have been notified from public health institutions, while 1.1 lakh were identified through private healthcare facilities

Granules India acquires Swiss Senn Chemicals to foray into peptide and CDMO business
Granules India acquires Swiss Senn Chemicals to foray into peptide and CDMO business

By IPP Bureau - February 22, 2025

The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market

Aster DM Healthcare to invest Rs. 850 crore in next 3 years in Kerala
Aster DM Healthcare to invest Rs. 850 crore in next 3 years in Kerala

By IPP Bureau - February 22, 2025

Aster commits to increase bed capacity in the State via capacity expansion and greenfield projects

Zydus receives final approval from USFDA for Ibuprofen and Famotidine Tablets, 800 mg/26.6 mg
Zydus receives final approval from USFDA for Ibuprofen and Famotidine Tablets, 800 mg/26.6 mg

By IPP Bureau - February 22, 2025

Ibuprofen and famotidine combination is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis

Roche Diagnostics India screens 5,000 children for eye health
Roche Diagnostics India screens 5,000 children for eye health

By IPP Bureau - February 21, 2025

Collaborates with VisionSpring to conduct eye check-up camps for underprivileged children

GSK's Nucala application for COPD accepted for review in China
GSK's Nucala application for COPD accepted for review in China

By IPP Bureau - February 21, 2025

Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally

Senores Pharmaceuticals acquires ANDA for Roflumilast 250 mcg and 500 mcg tablets
Senores Pharmaceuticals acquires ANDA for Roflumilast 250 mcg and 500 mcg tablets

By IPP Bureau - February 21, 2025

Wanbury reports 88% drop in Q3 FY25 PAT
Wanbury reports 88% drop in Q3 FY25 PAT

By IPP Bureau - February 21, 2025

Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25

KIMS enters into agreement to manage Splendid Hospitals, Hyderabad
KIMS enters into agreement to manage Splendid Hospitals, Hyderabad

By IPP Bureau - February 21, 2025

Krishna Institute of Medical Sciences Ltd enters into agreement with Splendid Hospitals

USFDA classifies Aurobindo Pharma Inc's warehouse as OAI
USFDA classifies Aurobindo Pharma Inc's warehouse as OAI

By IPP Bureau - February 21, 2025

The USFDA has determined the inspection classification status of this warehousing facility as 'Official Action Indicated

Korea’s MFDS completes inspection at Concord Biotech's Dholka unit
Korea’s MFDS completes inspection at Concord Biotech's Dholka unit

By IPP Bureau - February 21, 2025

The inspection was successfully completed

European Commission approves Biocon Biologics' Ustekinumab Biosimilar
European Commission approves Biocon Biologics' Ustekinumab Biosimilar

By IPP Bureau - February 21, 2025

YESINTEK, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease

Latest Stories

Interviews

Packaging